Emcure Pharmaceuticals Stock Current Ratio
| EMCURE Stock | 1,373 16.15 1.16% |
Emcure Pharmaceuticals fundamentals help investors to digest information that contributes to Emcure Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Emcure Stock. The fundamental analysis module provides a way to measure Emcure Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emcure Pharmaceuticals stock.
Emcure |
Emcure Pharmaceuticals Company Current Ratio Analysis
Emcure Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Emcure Pharmaceuticals has a Current Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Drug Manufacturers - Specialty & Generic industry. The current ratio for all India stocks is 100.0% higher than that of the company.
Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Emcure Fundamentals
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 295.8 B | ||||
| Shares Owned By Insiders | 86.77 % | ||||
| Shares Owned By Institutions | 3.53 % | ||||
| Price To Book | 9.39 X | ||||
| Price To Sales | 3.92 X | ||||
| Revenue | 69.17 B | ||||
| EBITDA | 12.05 B | ||||
| Book Value Per Share | 162.97 X | ||||
| Earnings Per Share | 26.38 X | ||||
| Target Price | 1575.0 | ||||
| Market Capitalization | 270.98 B |
About Emcure Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emcure Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emcure Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emcure Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Emcure Stock
Emcure Pharmaceuticals financial ratios help investors to determine whether Emcure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Emcure with respect to the benefits of owning Emcure Pharmaceuticals security.